Aegis Wealth Management LLC Buys Shares of 12,896 Pfizer Inc. (NYSE:PFE)

Aegis Wealth Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 12,896 shares of the biopharmaceutical company's stock, valued at approximately $342,000.

• Pfizer's 7.5% Dividend: Income Haven or House of Cards?

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

• 3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows

Check Out Our Latest Stock Report on PFE

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.61 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm's 50 day moving average price is $23.28 and its 200-day moving average price is $25.12. The stock has a market capitalization of $134.23 billion, a PE ratio of 16.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

• 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the firm posted $0.82 EPS. The business's quarterly revenue was down 7.8% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.29%. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

• Five stocks we like better than Pfizer
• Industrial Products Stocks Investing
• 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
• How to Plot Fibonacci Price Inflection Levels
• Tesla: Why Analysts Think It Could Jump Another 47%
• What is the Nikkei 225 index?
• Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here